阿奇霉素治疗小儿支原体肺炎的疗效观察

目的探讨阿奇霉素治疗支原体肺炎的临床疗效。方法选择临床诊断为支原体肺炎的患儿160例，随机分为两组，阿奇霉素（治疗）组、红霉素（对照）组各80例，治疗组按10mg／（kg·d）给予注射用阿奇霉素静脉滴注，对照组给予红霉素15—30mg／（kg·d）静脉滴注。结果治疗组和对照组总有效率分别为97．5％和90．0％，两组比较差异有统计学意义（P〈0．05），阿奇霉素出现的胃肠道反应、局部疼痛等不良反应明显低于红霉素（P〈0．05）。结论阿奇霉素治疗小儿支原体肺炎明显优于红霉素，是一种安全、有效的药物，值得临床上推广使用。

Azithromycin Efficacy of Mycoplasma Pneumonia in Children

Objective To investigate the azithromycin in the treatment of mycoplasma pneumonia patients. Methods Clinical diagnosis of 160 cases of mycoplasma pneumonia were randomly divided into two groups, azithromycin （treatment） group and erythromycin （control） group. 80 patients in treatment group were treated by azithromycin 10mg/（kg · d） intravenous injection and control group received erythromycin 15-30mg/（kg · d） intravenously. Results The total effective rate of treatment group and control group was 97.5% and 93.7%, the difference was statistically significant（P〈0.05）. The incidence of gastrointestinal reactions, local pain and other adverse reactions of azithromycin was lower than that of erythromycin（P〈0.05）. Conclusion Azithromycin is superior to erythromycin in the treatment of mycoplasma pneumonia in children. It is a safe and effective drug, and worth clinically widely used.